Norditropin FlexPro 15 mg/1.5 ml Growth-Hormone Pen
15 mg · 1.5 ml · Norditropin FlexPro is a precision growth-hormone pen for subcutaneous somatropin delivery — ideal for lean mass, bone density, and GHD modeling, with field-ready storage and rapid IGF-1 activation.
€ 149.00
Add to wishlist Add to compare
Beschreibung
Norditropin FlexPro 15 mg/1.5 ml Growth-Hormone Pen
Brand: Novo Nordisk
Content: 15 mg recombinant somatropin per 1.5 ml (10 mg/ml)
Price: €149
Manufactured in: Europe
🧪 Product Overview
Norditropin FlexPro delivers 191-amino-acid recombinant somatropin (rDNA origin) in a single-use, pre-filled growth hormone pen designed for precision subcutaneous administration in controlled research. Each 1.5 ml pen contains 15 mg of somatropin (10 mg/ml concentration), with a molecular weight of 22,125 Da, formulated for research into growth-hormone deficiency (GHD), body composition shifts, and IGF-1-mediated regeneration.
Post-activation, the FlexPro pen remains stable at ≤25 °C for 3 weeks or 2–8 °C for 4 weeks, allowing convenient field-based protocols. Trials show robust support for lean-mass gain, height velocity normalization in pediatric GHD, and erythropoietic stimulation via the IGF-1 axis. All use is governed by WADA Prohibited List S2 due to doping relevance.
✅ Key Research Highlights
Paediatric growth acceleration:
Clinical data confirm normalized height velocity within 6 months in GHD subjects [NovoMedLink, FDA]
Body composition support:
Studies in adult GHD cohorts show ↑ lean mass and ↓ fat mass after 6–12 months [Norditropin.com]
Erythropoietic enhancement:
Somatropin elevates IGF-1 and erythropoietin, improving haemoglobin levels [FDA Access Data]
Convenient storage:
Remains stable for 3 weeks at ≤25 °C after first use — ideal for outpatient settings [Norditropin.com]
🧬 Suggested Laboratory Applications
-
Growth-hormone deficiency (GHD) modeling in pediatric and adult cohorts
-
Somatropin-driven body recomposition and lean-mass trials
-
IGF-1 mediated bone mineralization and BMD research
-
Erythropoiesis and hematologic growth factor studies
-
Subcutaneous peptide delivery system evaluation
📊 Technical Specifications
| Field | Data |
|---|---|
| Chemical Name | Somatropin (rDNA origin, 191 amino acids) |
| Chemical Formula | C<sub>990</sub>H<sub>1528</sub>N<sub>262</sub>O<sub>300</sub>S<sub>7</sub> |
| Synonyms | Human Growth Hormone; rhGH; Norditropin; Recombinant hGH |
| Molecular Weight | 22,125 Da |
| CAS Number | 12629-01-5 |
| Half-life | Not listed — typically 2–4 hours subcutaneous (research dependent) |
| Detection Window | Varies based on dosage and clearance pathway |
| Documented Benefits | ↑ Growth velocity, ↑ lean mass, ↓ fat mass, ↑ BMD, ↑ EPO/IGF-1 |
| Main Risks | Edema, injection-site rash, arthralgia, insulin resistance, rare intracranial hypertension |
| Total Active Compound | 15 mg somatropin per pen (10 mg/ml × 1.5 ml) |
| Shelf-life | 30 months (refrigerated, unopened); 3–4 weeks post-activation |
❄️ PubChem-Supported Research Insights
-
Stimulates linear growth in pediatric GHD models
-
Enhances protein synthesis and lean mass retention in adult GHD
-
Modulates IGF-1 axis to support bone density improvements
-
Shown to improve red blood cell production via EPO stimulation
-
Offers convenient subcutaneous delivery with high compliance
⚠️ Documented Research Side Effects
-
Mild: Edema, arthralgia, injection-site rash
-
Moderate: Hyperglycaemia and reduced insulin sensitivity
-
Rare: Intracranial hypertension in long-term studies
-
Storage and refrigeration required to prevent protein degradation
🧯 Handling & Compliance
For Research Use Only — Not for human or veterinary treatment
Store refrigerated at 2–8 °C (unopened); post-activation use within 3 weeks at ≤25 °C
Use only with NovoFine or NovoTwist 8 mm single-use needles
Listed on WADA Prohibited List S2 — peptide hormone; exposure triggers anti-doping violations
There are no reviews yet.
